tbuckley/cabot-search huggingface dataset:
Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
Authors: Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Targeting CD79B using antibody–drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast with ADCs with heterogeneous loads. Patients and Methods: This phase 1 study enrolled 60 patients with histologically confirmed B-NHL that had relapsed/failed to respond following ≥1 prior treatment regimens; 41 (68%) had diffuse large B-cell lymphoma (DLBCL). Fifty-one patients received DCDS0780A monotherapy once every 3 weeks (0.3–4.8 mg/kg); 9 received combination therapy (3.6–4.8 mg/kg) with rituximab. Results: Fifty-four (90%) patients experienced adverse events related to study drug, the most common of which were blurred vision, fatigue, corneal deposits, neutropenia, nausea, and peripheral neuropathy. 4.8 mg/kg was the highest dose tested and the recommended phase II dose. The pharmacokinetic profile was linear at doses ≥1.2 mg/kg. Response rate in all-treated patients (N = 60) was 47% (n = 28), including 17 complete responses (28%) and 11 partial responses (18%). The median duration of response (15.2 months) was the same for all responders (n = 28) and patients with DLBCL (n = 20). Conclusions: DCDS0780A as the TDC format for CD79B was tested at higher doses than its ADC counterpart investigated earlier, leading to deep responses. However, dose intensity was limited by ocular toxicities seen at the higher doses indicating that the TDC format was unable, in the current study, to expand the therapeutic index for the CD79B target. The encouraging antitumor activity advocates continuation of investigations into novel ADC technologies.
Ablation of non-infarct related ventricular tachycardia in patients with prior myocardial infarction Luis R. P. Scott, Giselle Gervacio-Domingo, Gregory T. Altemose, Mark A. Coppess, Jeffrey E. Olgin, Douglas P. Zipes, John M. Miller. Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN
Journal: Journal of the American College of Cardiology (2001)
Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters
Authors: Lunzhi Yuan, Ming Zhou, Jian Ma, Xuan Liu, Peiwen Chen, Huachen Zhu, Qiyi Tang, Tong Cheng, Yi Guan, Ningshao Xia
Journal: Cellular and Molecular Immunology (2022)
New and Nonofficial Remedies
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
Authors: Peiyan Yuan, Fen Yang, Si Si Liew, Jiachang Yan, Xiao Dong, Jinfeng Wang, Shubo Du, Xin Mao, Liqian Gao, Shao Q. Yao
Journal: Biomaterials (2022)
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
Authors: Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E Santiago-Walker, Manish Monga, Anne O'Hagan, Yohann Loriot, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott Tagawa, Aude Flechon, Boris Alexeev, Sergey Varlamov, Robert Huddart, Earle Burgess, Arash Rezazadeh, Arlene Siefker-Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begona Mellado, Omi Parikh, Peter Schatteman, Stephane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio Scagliotti, Giovanni Schinzari, Jae Lyun Lee, Mikhail Shkolnik, Mark Fleming, Monica Joshi, Peter O'Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, Remy Delva, Frederic Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, Cristina Cebotaru, Ignacio Duran, Victor Moreno, Jose Luis Perez Gracia, Alvaro Pinto, Wen-Pin Su, Shian-Shiang Wang, John Hainsworth, Ian Schnadig, Sandhya Srinivas, Nicholas Vogelzang, Wolfgang Loidl, Johannes Meran, Marine Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, Susanne Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauss, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora Nanette Sternberg, Sun Young Rha, Iurie Bulat, Adel Izmailov, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, Maribel Saez, Isabel Syndikus, Kathryn Tarver, Leonard Appleman, John Burke, Nancy Dawson, Sharad Jain, Yousef Zakharia
Journal: The Lancet Oncology (2022)
SELECTIONS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD
Authors: Mary P. Moore, Rory P. Cunningham, Grace M. Meers, Sarah A. Johnson, Andrew A. Wheeler, Rama R. Ganga, Nicole M. Spencer, James B. Pitt, Alberto Diaz‐Arias, Ahmed I. A. Swi, Ghassan M. Hammoud, Jamal A. Ibdah, Elizabeth J. Parks, R. Scott Rector
Journal: Hepatology (2022)

NAFLD and its more-advanced form, steatohepatitis (NASH), is associated with obesity and is an independent risk factor for cardiovascular, liver-related, and all-cause mortality. Available human data examining hepatic mitochondrial fatty acid oxidation (FAO) and hepatic mitochondrial turnover in NAFLD and NASH are scant.To investigate this relationship, liver biopsies were obtained from patients with obesity undergoing bariatric surgery and data clustered into four groups based on hepatic histopathological classification: Control (CTRL; no disease); NAFL (steatosis only); Borderline-NASH (steatosis with lobular inflammation or hepatocellular ballooning); and Definite-NASH (D-NASH; steatosis, lobular inflammation, and hepatocellular ballooning). Hepatic mitochondrial complete FAO to CO2 and the rate-limiting enzyme in β-oxidation (β-hydroxyacyl-CoA dehydrogenase activity) were reduced by ~40%-50% with D-NASH compared with CTRL. This corresponded with increased hepatic mitochondrial reactive oxygen species production, as well as dramatic reductions in markers of mitochondrial biogenesis, autophagy, mitophagy, fission, and fusion in NAFL and NASH.These findings suggest that compromised hepatic FAO and mitochondrial turnover are intimately linked to increasing NAFLD severity in patients with obesity.
Physical medicine and rehabilitation
Authors: B. S. Smith
Journal: JAMA (1989)

CONTEMPO last reviewed the specialty of physical medicine and rehabilitation (physiatry) in October 1986.<sup>1</sup>During that seemingly brief span of time, changes in the field have been remarkable. It has expanded in numbers, in breadth, and in scientific application. The most obvious track of the numerical growth in physiatry can be seen through the rapid increase in residency positions.<sup>2</sup>In the 1985-1986 academic year, there were 819 residency positions available; 795 of these (97%) were filled. For the 1988-1989 academic year, there were 1005 positions offered, and 984 (98%) were filled. This is an increase of 23% in only 3 years. Similarly, there has been an increasing percentage of American medical graduates filling these positions. In 1981, only 51% of residents were graduates of American medical schools. For the 1988-1989 academic year, 91% are American graduates. The specialty is composed largely of young physicians. In 1988, Gonzalez et
Neurological Surgery
Authors: George T. Tindall
Journal: JAMA (1989)

The pace of progress in medicine generally and in neurosurgery specifically is quickening. New technologies, innovative diagnostic procedures, improved treatment modalities, and refined surgical techniques continue to appear with regularity. Computed tomographic scans, magnetic resonance imaging, microsurgery, laser applications, transsphenoidal microsurgery, medical therapies for pituitary tumors, endovascular therapy, brain implants, spine surgical techniques, stereotaxic radiosurgery—these and many other developments have contributed to the evolving and effective practice of neurosurgery today. Innovation and expansion will no doubt be ongoing for some time. But for the present, there are a few areas in which there has been considerable recent progress and that impact particularly on the practice of neurosurgery. Those that are covered in this article have made important inroads; the order in which they are presented is arbitrary. Increasingly sophisticated surgical techniques, better understanding of surgical anatomy (especially of the structure and anatomic relationships of the cavernous sinus), and more widespread
Assessment of the 12-Lead Electrocardiogram as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age)
Authors: Barry J. Maron, Richard A. Friedman, Paul Kligfield, Benjamin D. Levine, Sami Viskin, Bernard R. Chaitman, Peter M. Okin, J. Philip Saul, Lisa Salberg, George F. Van Hare, Elsayed Z. Soliman, Jersey Chen, G. Paul Matherne, Steven F. Bolling, Matthew J. Mitten, Arthur Caplan, Gary J. Balady, Paul D. Thompson
Journal: Journal of the American College of Cardiology (2014)
Afebrile Bacteremia
Authors: Richard Gleckman
Journal: JAMA (1982)

A prospective study was performed in 25 elderly patients who experienced afebrile bacteremia during a 1.5-year interval. An explanation for the afebrile state was explored. Subtle findings, such as unexplained alterations in mental status or presence of leukocytosis, proved to be invaluable guides for performing blood cultures. Afebrile nosocomial bacteremias usually occurred as a complication of a malignant process or an intravascular catheter, and these episodes were invariably fatal. (<i>JAMA</i>1982;248:1478-1481)
Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial.
Authors: Xuewei Ding, Bin Li, Qiang Xue, Mingzhi Cai, Jingli Cui, Baogui Wang, Bin Ke, Rupeng Zhang, Han Liang
Journal: Journal of Clinical Oncology (2022)

294 Background: Perioperative treatment is very important to improve long-term survival for gastric/gastroesophageal junction cancer(GC/GEJC), The RESOLVE study showed that perioperative-SOX have a clinically meaningful improvement in patients with locally advanced GC/GEJC who had D2 gastrectomy. Adding PD-1 inhibitor to the chemotherapy have shown significant clinical benefits in first-line treatment of GC/GEJC. This trial was designed to assess the feasibility and efficacy of this combination in perioperative treatment of resectable locally advanced GC/GEJC. Methods: This is a prospective, single-arm, single-center phase II study. Patients of histopathology confirmed locally advanced GC/GEJC, with clinical stage II-IV A per AJCC8 th , ECOG PS 0-1, were enrolled and treated with 3 cycles of preoperative sintilimab (200mg, iv, d1) and SOX (oxaliplatin 130mg/m 2 , iv, d1 and S-1 40-60mg, po, bid, d1-14) every 3 weeks, and 12 months of postoperative sintilimab (200mg, iv, d1) and S-1 (40-60mg, po, bid, d1-14) every 3 weeks. The primary endpoint was 2-year DFS rate. The second endpoints were pCR, MPR, R0 resection rate, safety and 3-year OS. Results: As of June 2021, 21 patients were enrolled, with median age 56 years (range 31-72 years), males 10 (47.6%), cT2/3/4a/4b 2(9.5%)/0/16(76.2%)/3(14.3%), cN1/N2 7(33.3%)/14(66.7%) and GC/GEJC 14(66.7%)/7(33.3%). All 21 patients had completed gastrectomy. 7 patients (33.3%) achieved pathological complete response (pCR), 8 patients (38.1%) had major response (TRG 0-1) and 21 patients (100%) achieved R0 resection. Common TRAEs were anemia (38.1%), lymphopenia (28.6%), neutropenia (19.0%), leukopenia (14.3%), ALT increase (9.5%), AST increase (4.8%), thrombocytopenia (4.8%). Grade 3 or more TRAEs included anemia (9.5%). There were no severe complications and death related to the operation. The median postoperative hospital stay was 10 days (range 7-41 days). Conclusions: Adding sintilimab to the chemotherapy resulted in an encouraging pCR and MPR as perioperative treatment for resectable locally advanced GC/GEJC, and safety was manageable. A Phase II randomized study is ongoing. Clinical trial information: ChiCTR2100043572.
Abstract P014: Lower eGFR and Proteinuria Were Independently Associated With Lower Cognitive Abilities in Community-dwelling Men in Japan: SESSA study
Authors: Akira Fujiyoshi, Takayoshi Ohkubo, Katsuyuki Miura, Akihiko Shiino, Naoko Miyagawa, Naoyuki Takashima, Yoshino Saitoh, Sayuki Torii, Aya Kadota, Sayaka Kadowaki, Takashi Hisamatsu, Itsuko Miyazawa, Ikuo Tooyama, Hirotsugu Ueshima
Journal: Circulation (2017)

Introduction: The relationship between chronic kidney disease (CKD) and cognitive function remains to be determined. Existing studies focused primarily on estimated glomerular filtration rate (eGFR) but not proteinuria in relation to cognitive function. Hypothesis: In a community-based sample, lower eGFR and presence of proteinuria are cross-sectionally independently associated with lower cognition. Methods: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA) randomly recruited and examined participants from Shiga, Japan in 2006-08 at baseline. Among 824 male participants in the follow-up exam (2010-12), we restricted our analyses to those who underwent the Cognitive Abilities Screening Instrument (CASI), age ≥65 years-old, free of stroke, with no missing pertinent covariates. We calculated eGFR (creatinine-based) according to the 2012-guideline by the Japanese Society of Nephrology. We then divided the participants into three groups by eGFR of ≥60, 59-40, and &lt;40 (mL/min/1.73m 2 ), and separately divided into three groups according to proteinuria using urine dipstick: (-), (-/+), and ≥(1+). We defined CKD as either eGFR &lt;60 or proteinuria ≥ (-/+). In linear regression with CASI score being a dependent variable, we computed the score adjusted for age, highest education attained, smoking, drinking, body mass index, hypertension, diabetes, and dyslipidemia. Results: We analyzed 541 men. The mean [standard deviation] of age and unadjusted score were 72.6 [4.3] years and 89.7 [6.0]. Prevalence of CKD was 56%. The score was significantly lower in participants with CKD than those without it (P=0.03). eGFR and proteinuria categories were separately and jointly associated with lower CASI score in a graded fashion (Ps for trend &lt;0.05 in all the models tested. Table 1 ). Conclusions: Lower eGFR and higher degree of proteinuria were independently associated with lower cognitive function in the community-based men. CKD even in its early phase may predispose to lower cognitive function.
Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Noah D. Peyser, Hua Li, Yan Zeng, Erin Isaacson Wechsler, Max V. Ranall, Sourav Bandyopadhyay, Umamaheswar Duvvuri, Theresa M. LaVallee, Richard C.K. Jordan, Daniel E. Johnson, Jennifer R. Grandis
Journal: Clinical Cancer Research (2021)

In the original version of this article (1), the same image was used for the p-HER3-Y1197 and HER3 panels of the SCC47 cell line in Fig. 3A. All of the SCC47 panels in Fig. 3A have been updated in the latest online HTML and PDF versions of the article. The authors regret this error.
Deaths
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy
Authors: Yang Li, Jianfeng Gao, Shuping Wang, Shijun Li, Xiaowen Hou, Yanna Pan, Jialu Gao, Xue Qiao, Zhiquan Tian, Deliang Chen, Hai Deng, Zixin Deng, Xuechuan Hong, Yuling Xiao
Journal: Journal of Controlled Release (2022)

Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers self-assembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.
Greater understanding about hair loss caused by chemotherapy
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Piccini et al. Br J Dermatol 2022; 186:129–141. One of the more severe and most-feared side-effects of chemotherapy is hair loss, which can significantly affect the quality of life of patients undergoing these treatments. Sometimes, this can even lead to rejection of treatment by patients, especially women. Luckily, in almost all patients, the hair regrows within 3 months of stopping treatment. However, in some patients, hair loss can be permanent and this can result in substantial distress. Unfortunately, there are no established treatments to prevent or restore hair growth in these patients. In this international study, we used hair samples taken from the scalp of healthy people to induce a condition that simulates the effects of chemotherapy in patients with cancer in the laboratory. We showed that chemotherapy can result in damage to the cells in the hair follicle that are responsible for replenishing the cells in charge of hair growth, a subset of cells called stem cells. Not only does chemotherapy bring about events that eventually resulted in death of these stem cells, but it can also stimulate the transformation of these cells into scarring tissue, an irreversible process that prevents the growth of new hairs. With this greater understanding of the mechanisms that lead to hair damage, we have tried using a compound, called NAGED (N-acetyl-GED-0507-34-Levo), to protect the stem cells from depletion and damage in the laboratory. Although still far from being able to use this new information in a clinical setting, this study offers hope for the development of a potential treatment that could be applied to the scalp and that can be used to potentially prevent permanent hair loss in patients with cancer undergoing chemotherapy. Linked Article: Piccini et al. Br J Dermatol 2022; 186:129–141.